RSS   Newsletter   Contact   Advertise with us
Post Online Media

Edge Therapeutics appoints chief operating officer

Edge TherapeuticsEdge Therapeutics, Inc., a clinical-stage biotechnology company, announced the appointment of Daniel Brennan to the newly created position of chief operating officer.
Article continues below

READ MORE Flexion Therapeutics appoints Mark Stejbach to board

Mr. Brennan joins Edge with about 20 years of senior-level management, commercial and business development experience in the biopharmaceutical industry.

Most recently, Mr. Brennan served as Chief Operating Officer and Executive Vice President of Insys Therapeutics, Inc. since November 2015, where he was responsible for all commercial and general operating activities, including rebuilding Insys’ commercial leadership team and practices.

Previously, Mr. Brennan held multiple leadership positions at Lundbeck, Inc., including serving as Vice President and Group General Manager of the Neurology Business Unit and U.S. Business Development Group, where he led the launch of four specialty orphan products.

Prior to Lundbeck, Mr. Brennan served at Abbott Laboratories, where he led sales and product launch preparation for the company’s acute care hospital product pharmaceutical group.

He also brings sales, marketing and new product development expertise from his decade of service at Eli Lilly and Company.

Mr. Brennan received a B.A. from the University of Notre Dame and an M.B.A. degree, with distinction, from the Kellogg Graduate School of Business at Northwestern University.



We use cookies to ensure that we give you the best experience on our website. Please allow cookies for fully-functioning website.

Allow Cookies Privacy Policy